MedTrace Logo

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

NCT00271167 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2015-03-25

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures whether INO-1001 reduces the side effects caused by heart-lung bypass machines.

Conditions

  • Heart Diseases
  • Postoperative Complications

Interventions

DRUG

INO-1001

Sponsors & Collaborators

  • Inotek Pharmaceuticals Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2006-06-30

Countries

  • United States
  • Australia
  • India
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271167 on ClinicalTrials.gov